Kevin Haas was named Chief Development and Technology Officer of Veracyte, Inc., effective March 24, 2026. As of November 15, 2026, Veracyte, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 16, 2026, naming 1 appointment (Form 8-K, March 16, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Veracyte, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Veracyte, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Veracyte, Inc. files it.
Also on the record for Veracyte, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 12, 2026 | Stake report, Schedule 13G/A, by Artisan Partners Asset Management Inc. | 2.9% of the class | 5%+ stakes | Source |
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.7% of the class | 5%+ stakes | Source |
| September 14, 2026 | Acquired Convergent Genomics Inc. | $150M | Acquisition | Source |
| June 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.1% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Artisan Partners Asset Management Inc. | 6.9% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 6.3% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.7% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.2% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.67% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.2% of the class | 5%+ stakes | Source |
| February 3, 2026 | Stake report, Schedule 13G/A, by Artisan Partners Asset Management Inc. | 7.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Veracyte, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Veracyte, Inc. and the records around it.
Veracyte, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Acquisition Sep 2026
- Who owns it
Companies that share a holder
- Artisan Partners Asset Management Inc. also filed stake reports on 17 other companies: HENRY SCHEIN, INC. (Nov 2026), iRhythm Holdings, Inc. (Nov 2026), KORNIT DIGITAL LTD. (Nov 2026)
- ARK Investment Management LLC also filed stake reports on 23 other companies: Beam Therapeutics Inc. (Nov 2026), CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026)
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
Watch Veracyte, Inc.
Get an email when Veracyte, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Veracyte, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Veracyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Veracyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-16 | In | Chief Development and Technology Officer | 2026-03-24 | 8-K, 2026-03-16 |
Who leads Veracyte, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Development and Technology Officer: Kevin Haas, appointed, effective 2026-03-24 (filed 2026-03-16).
New leaders reset buying decisions — get the Full Report on Veracyte, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Development and Technology Officer at Veracyte, Inc., with the record behind each one.
Find candidates like Chief Development and Technology Officer at Veracyte, Inc.Every change, in the filing's words
Appointed: Kevin Haas, Chief Development and Technology Officer, effective 2026-03-24
On March 16, 2026, Veracyte, Inc. (the "Company") announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026.
- Prior to joining the Company, Dr. Haas served as Chief Technology Officer of Myriad Genetics, Inc. (NASDAQ: MYGN), a genetic testing and precision medicine company, a position he held since February 2021.
- Previously, Dr. Haas served as Senior Vice President of Technology and Senior Vice President of Engineering at Myriad and as Vice President and Senior Director of Bioinformatics at Myriad Women's Health.
- Dr. Haas received a B.S. in Chemical Engineering from the University of Wisconsin-Madison and a Ph.D. in Chemical Engineering from the University of California, Berkeley.
- The equity awards will be granted under the Company's 2023 Equity Incentive Plan and the applicable award agreements.
Tools for this story
Each opens in a new tab, filled in for Veracyte, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
